Page 4 - Independent Data News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Achilles Therapeutics Announces Independent Data and Safety Monitoring Committee Review with a Positive Recommendation to Continue with Current Study Design of the Phase I/IIa CHIRON and THETIS Trials Phase I/IIa CHIRON and THETIS Trials London, UK 5 February 2021 - Achilles Therapeutics ("Achilles" or the "Company"), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that an Independent Data and Safety Monitoring Committee (IDSMC) has completed its first review of the ongoing, first-in-human Phase I/IIa CHIRON and THETIS tr...

Revive Therapeutics plans to apply for emergency use authorization of its drug Bucillamine as a treatment for the indication.

The Deal Would Create the Largest Enterprise in the Cannabis Industry By Revenue Shares of Canadian Licensed-Producers (LPs) Aphria (TSX:APHA) (NYSE:APHA) (FRA: 10E)  and Tilray (NASDAQ:TLRY) (FRA: 2HQ)  traded higher following the news about the two companies merging. Benzinga caught up with Aphria CEO and chairman Irwin D. Simon, who will maintain those two positions in the new company, and Tilray CEO Brendan Kennedy, who will serve in the new corporation’s board of directors alongside one other person picked by Tilray, and seven others (including Simon) from Aphria. Source: ...

Published: Dec 24, 2020 By Alex Keown The European Union (EU) authorized ViiV Healthcare’s Vocabria (cabotegravir injection and tablets) in conjunction with Janssen’s Edurant (rilpivirine tablets) for the treatment of HIV-1 infection in adults who are virologically suppressed. Vocabria is intended for adults who are virologically suppressed on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class. The approval of ViiV’s treatment is the first time HIV-1 patients in Europe m...

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Plans on Emergency Use Access Revive Therapeutics Ltd. a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19. The Company is on pace to meet its enrollment goals for the … Revive Therapeutics Ltd. (“Revive” or the “Co...